Biodesix shares jump 10.27% intraday after reporting positive Q4 2025 EBITDA and 41% revenue growth.

Biodesix (NASDAQ:BDSX) surged 10.27% intraday after reporting preliminary fourth-quarter 2025 results that exceeded expectations. The company achieved positive adjusted EBITDA, a key profitability milestone, alongside 41% year-over-year revenue growth to $28.8 million. Strong lung cancer testing volumes, improved cash flow, and a reorganized sales force driving primary care channel adoption further bolstered investor sentiment. Analyst Canaccord Genuity reiterated a Buy rating with a $20 price target, citing operational leverage and improved insurer partnerships. The results marked a turnaround from a mixed third-quarter performance and validated Biodesix’s path to sustainability.